TABLE 2.
Adequacy for site and for diagnosis in CB with respective final cytological diagnosis
| Total CB | 464 | |
|---|---|---|
| Adequate for site | 448 | 95.5% |
| Adequate for diagnosis | 430 | 92.6% |
| Primitive lung cancer | 238 | 55% |
| Adenocarcinoma | 157 | 66% |
| Squamous cell carcinoma | 33 | 13.8% |
| SCLC | 35 | 14.7% |
| Carcinoma, NOS | 4 | 2% |
| Lymphoma (Hodgkin's lymphoma) | 3 | 1.35% |
| Carcinoid | 3 | 1.35% |
| Combined NSCLC + SCLC | 2 | 0.8% |
| Mesothelioma | 1 | 0.2% |
| Metastasis to lung | 39 | 9% |
| Lower GI (colon‐rectum) | 5 | 12.8% |
| Breast | 12 | 30.7% |
| Kidney/bladder/prostate | 10 | 25.6% |
| Head and neck | 1 | 3.3% |
| Melanoma | 1 | 3.3% |
| Upper GI (esophagus/stomach/pancreas) | 3 | 7.8% |
| Sarcoma | 1 | 3.3% |
| Cordoma | 1 | 3.3% |
| Female genital tract | 4 | 9.9% |
| Lymphoid tissue | 104 | 24% |
| Inflammatory/necrotizing granulomas | 15 | 3.3% |
|
Non‐necrotizing granuloma (suggestive of sarcoidosis) Abbreviations: CB, cell block; GI, gastrointestinal; NOS, not otherwise specified; NSCLC, non‐small cell lung cancer; SCLC, small cell lung cancer |
29 | 8% |